Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit
Rani Therapeutics Holdings, Inc. - Class A (RANI)
Company Research
Source: GlobeNewswire
SAN JOSE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024 from 11:30 am – 12:00 pm E.T. in Track 2. Interested parties can register and access the live webcast for the conference here. About Rani Therapeutics Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has
Show less
Read more
Impact Snapshot
Event Time:
RANI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RANI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RANI alerts
High impacting Rani Therapeutics Holdings, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RANI
News
- Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin TriagonistGlobeNewswire
- Rani Therapeutics to sell 3M shares at $3.00 in registered direct offering [Seeking Alpha]Seeking Alpha
- Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing WarrantsGlobeNewswire
- Oppenheimer Predicts up to 740% Rally for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]Yahoo! Finance
RANI
Earnings
- 8/6/24 - Beat
RANI
Analyst Actions
- 10/18/24 - HC Wainwright
RANI
Sec Filings
- 10/17/24 - Form SC
- 10/17/24 - Form 4
- 10/16/24 - Form 8-K
- RANI's page on the SEC website